Thus, the contribution of RIPK3 in NAFLD pathology varies in different experimental models, and the role of RIPK3 in human patients with NAFLD needs to be determined in the future. This evidence concerns the gene RIPK3 and metabolic dysfunction-associated steatotic liver disease.